Treatment of OCI-AML3 cells or primary NPMc+ AML blasts (BM1) with JQ1 or I-BET151 substantially increased the expression of NPM1/NPMc+ and HEXIM1 while concomitantly reducing the expression of Bcl2 (Figure 3A, 3B, and 3C). This evidence concerns the gene HEXIM1 and acute myeloid leukemia.